The estimated Net Worth of Cary L Queen is at least $7.08 Miliard dollars as of 23 December 2005. Cary Queen owns over 15,000 units of PDL Biopharma Inc stock worth over $7,074,250,800 and over the last 21 years Cary sold PDLI stock worth over $2,659,200.
Sign up
Cary Queen PDLI stock SEC Form 4 insiders trading
Cary has made over 14 trades of the PDL Biopharma Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Cary sold 15,000 units of PDLI stock worth $450,000 on 23 December 2005.
The largest trade Cary's ever made was exercising 95,000 units of PDL Biopharma Inc stock on 21 May 2004 worth over $380,000. On average, Cary trades about 14,211 units every 31 days since 2003. As of 23 December 2005 Cary still owns at least 1,961,800 units of PDL Biopharma Inc stock.
You can see the complete history of Cary Queen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Cary Queen's mailing address?
Cary's mailing address filed with the SEC is , , , , .
Insiders trading at PDL Biopharma Inc
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain oraz Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
What does PDL Biopharma Inc's logo look like?
Complete history of Cary Queen stock trades at PDL Biopharma Inc
PDL Biopharma Inc executives and stock owners
PDL Biopharma Inc executives and other stock owners filed with the SEC include:
-
Dominique Monnet,
President, Chief Executive Officer, Director -
Christopher Stone,
Vice President, General Counsel, Secretary -
Edward Imbrogno,
Chief Financial Officer, Chief Accounting Officer, Vice President - Finance -
John McLaughlin,
Director -
David Gryska,
Independent Director -
Elizabeth O'Farrell,
Chairperson of the Board -
Natasha Hernday,
Independent Director -
Alan Bazaar,
Independent Director -
Danny J Jr. Hart,
Assoc Genl Counsel/Asst Sec -
Samuel R Saks,
Director -
Jody S Lindell,
Director -
Paul R Edick,
Director -
Harold E Selick,
Director -
Paul W Sandman,
Director -
Peter S Garcia,
Vice President, CFO -
Steffen Pietzke,
Controller and CAO -
Shlomo Yanai,
Director -
Jill M. Jene,
VP, Business Development -
Christine R Larson,
VP & Chief Financial Officer -
Joseph Iii Klein,
Director -
Karen J Wilson,
VP of Finance & PAO -
Mark Anthony Mc Camish,
SVP & CMO -
Brett L Schmidli,
SVP, Technical Operations -
Gary A Lyons,
Director -
Andrew Guggenhime,
SVP & Chief Financial Officer -
Faheem Hasnain,
President & CEO -
Francis Willard Sarena,
Exec Dir/Chief Legal Off/Secy -
Herb Cross,
Corp Controller/Prin Acctg Off -
Richard /Ca/ Murray,
Sr. VP & CSO -
Steven E Benner,
SVP and Chief Medical Officer -
Bradford S Goodwin,
Director -
Laurence Jay Korn,
Chairman of the Board -
Karen A Dawes,
Director -
Jaisim Shah,
Vice President, Marketing -
Jon S Saxe,
Director -
L Patrick Gage,
Director -
Glen Y Sato,
SVP and CFO -
Cynthia Lynn Shumate,
VP Legal Affrs, Secy & CCO -
Cary L Queen,
Senior Vice President -
Peter H Calcott,
VP, Quality & Compliance -
Laurie C Torres,
VP, Human Resources -
David Iwanicki,
VP, Sales & Sales Operations -
Mark Mcdade,
Chief Executive Officer -
Robert Michael Ii Savel,
SVP Technical Operations -
Samuel Broder,
Director -
George Jue,
VP, Fin & Corp. Controller -
Max Link,
Director -
Sergio Garcia Rodriguez,
VP, Legal and General Counsel -
Lyn D Olson,
VP, Quality and Compliance -
Douglas O Ebersole,
SVP, Legal & Corp Development -
George M Gould,
Director -
Jurgen Drews,
Director -
Behrooz Najafi,
V.P. IS and Corporate Services -
Corine Klingbell,
VP, Preclinical Development -
William R Benjamin,
VP, Research & Clinical Tech -
Frances G Charlson,
VP, Human Resources -
Patrick M Caldwell,
VP, Finance and Controller -
Mark P Backer,
VP, Technical Development -
David Montez,
Controller and CAO -
Fred Frank,
Director -
Bruce Tomlinson,
Chief Financial Officer -
Caroline J Krumel,
Vice President of Finance -
Point Capital L.P.O'shea Ro...,